Market Cap 1.10B
Revenue (ttm) 348.97M
Net Income (ttm) 5.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 1.68%
Debt to Equity Ratio -8.78
Volume 9,543,200
Avg Vol 6,216,640
Day's Range N/A - N/A
Shares Out 308.80M
Stochastic %K 53%
Beta 1.04
Analysts Strong Sell
Price Target $7.06

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provi...

Industry: Biotechnology
Sector: Healthcare
Phone: 818 661 5000
Address:
1 Casper Street, Danbury, United States
Affizle
Affizle May. 9 at 3:18 AM
$MNKD Looks like Mike didn't buy those 100K shares after all. It was his wife. The stupid company mistakenly reported it was him but it wasn't. And it took the company two months to correct the mistake per the Form 4 released tonight. What a positively incompetent company Mannkind is. And it turns out the CEO's wife has bigger balls than her husband for buying shares out of pocket. 1. On March 10, 2026 Mr. Castagna filed a Form 4 that should not have been filed and which reported a transaction that should not, in fact, be attributable to him. The Form 4 mistakenly reported a direct acquisition of 100,000 shares of common stock of the Issuer on March 10, 2026 by Mr. Castagna (the "Shares"). The Shares, however, were acquired by Mr. Castagna's spouse under a segregated retirement account in which Mr. Castagna does not have a pecuniary interest. As a result, Mr. Castagna was not obligated to file a Form 4 pursuant to Section 16(a). Such Form 4 should be deemed revoked.
0 · Reply
jlonards
jlonards May. 9 at 1:02 AM
$MNKD I think we're good.
1 · Reply
Jw25nyc
Jw25nyc May. 8 at 10:39 PM
0 · Reply
grampslol
grampslol May. 8 at 8:42 PM
$MNKD remember the crappy scripts... New 292 refills 444... week ending 5/1/2026... approved in the USA in 2014...
0 · Reply
grampslol
grampslol May. 8 at 8:38 PM
$MNKD pennyland close...hump...
0 · Reply
zmanx
zmanx May. 8 at 8:32 PM
$MNKD nice c&h to get us back to $5-&6 range again
1 · Reply
Affizle
Affizle May. 8 at 8:15 PM
$MNKD who here also owns Lqda other than Clan, stevemano, and Nate? They stand to make a boat load of money on Monday. Lolz!
0 · Reply
ITrustno1
ITrustno1 May. 8 at 8:01 PM
$MNKD double PDUFA run up makes things interesting for all scenarios. Run up 1 incoming after the Q1 report sentiment dissipates next week. PDUFA 1 Approved Scenario What would the SELL THE NEWS crew do, knowing PDUFA 2 is set up just behind the 1st? PDUFA 1 CLR Scenario What would the SKY IS FALLING crew do, knowing PDUFA 2 is set up just behind the 1st? I don’t have an opinion on approval beyond the fact PDUfA 1 is an expansion for PEDS, so the drug is proven, the company has gotten through the FDA process for this specific product once already and should have a better understanding of what they needed to present to get this through. Volitility ahead for sure. Looking like Sub$3 isn’t going to hit… leveled off so far $3.5range +\- 15cents $4+ MIN looks to be the run up target over next two weeks IMO, just holding for a good re entry price myself.
0 · Reply
Kool_Aid_Mann
Kool_Aid_Mann May. 8 at 7:46 PM
$GME $AMC Come join $MNKD as they approach their May 29th pediatric PDUFA!! This is the one that they have been waiting for for 12 years. Lots of delays, but it is finally here and likely to be the milestone trigger for a big cash deal with big pharma! On top of that, they just got back the green light for Treprostinil DPI in IPF which had them previously trading over $6 until a spat with their partner $UTHR . Now, not only is everything copacetic again, but they have also just announced a new molecule colloboration with bigger potential than Trep, Ralinpag DPI! But wait, there's more, there is another PDUFA ahead for them for furoscix on July 26th, that will approve a new auto injector that will make this product best in class and reduce COGs by 70% to create massive profits. And lets not forget that nintedabib DPI just finished 1b and is prime for an upfront cash deal! Fireworks ahead, fight the Citadel!
1 · Reply
RockyRambo26
RockyRambo26 May. 8 at 7:30 PM
$MNKD Right now I think the shorts are crapping their pants trying to get out before the FDA approval this month!
5 · Reply
Latest News on MNKD
MannKind price target lowered to $7 from $8 at Mizuho

2026-05-07T15:49:43.000Z - 1 day ago

MannKind price target lowered to $7 from $8 at Mizuho


MannKind price target raised to $10 from $8 at Wells Fargo

2026-05-07T10:51:50.000Z - 1 day ago

MannKind price target raised to $10 from $8 at Wells Fargo


MannKind reports Q1 EPS (2c), consensus 1c

2026-05-07T01:17:30.000Z - 2 days ago

MannKind reports Q1 EPS (2c), consensus 1c


MannKind Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 days ago

MannKind Earnings Call Transcript: Q1 2026


MannKind price target lowered to $8 from $10 at Mizuho

2026-04-13T14:45:40.000Z - 25 days ago

MannKind price target lowered to $8 from $10 at Mizuho


MannKind price target lowered to $6 from $7 at Truist

2026-04-08T12:35:39.000Z - 4 weeks ago

MannKind price target lowered to $6 from $7 at Truist


MannKind Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 3:40 PM EDT - 2 months ago

MannKind Transcript: Leerink Global Healthcare Conference 2026


MannKind Announces Settlement of Convertible Senior Notes

Mar 5, 2026, 4:30 PM EST - 2 months ago

MannKind Announces Settlement of Convertible Senior Notes


MannKind price target lowered to $8 from $10 at Wedbush

2026-03-05T14:03:29.000Z - 2 months ago

MannKind price target lowered to $8 from $10 at Wedbush

UTHR


MannKind to Participate in Upcoming Investor Conferences

Mar 4, 2026, 9:00 AM EST - 2 months ago

MannKind to Participate in Upcoming Investor Conferences


MannKind price target lowered to $7 from $8 at Wells Fargo

2026-02-27T12:57:54.000Z - 2 months ago

MannKind price target lowered to $7 from $8 at Wells Fargo


MannKind price target lowered to $8 from $11 at H.C. Wainwright

2026-02-27T12:11:17.000Z - 2 months ago

MannKind price target lowered to $8 from $11 at H.C. Wainwright


MannKind Earnings Call Transcript: Q4 2025

Feb 26, 2026, 9:00 AM EST - 2 months ago

MannKind Earnings Call Transcript: Q4 2025


MannKind reports Q4 EPS (5c) vs 3c last year

2026-02-26T13:23:42.000Z - 2 months ago

MannKind reports Q4 EPS (5c) vs 3c last year


MannKind Provides Business Updates and 2026 Growth Drivers

Jan 8, 2026, 8:05 AM EST - 4 months ago

MannKind Provides Business Updates and 2026 Growth Drivers


MannKind Shares FUROSCIX® Business Updates

Dec 23, 2025, 8:05 AM EST - 4 months ago

MannKind Shares FUROSCIX® Business Updates


MannKind Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 6:30 AM EST - 6 months ago

MannKind Transcript: Jefferies London Healthcare Conference 2025


MannKind Transcript: Study Update

Nov 10, 2025, 9:00 AM EST - 6 months ago

MannKind Transcript: Study Update


MannKind Earnings Call Transcript: Q3 2025

Nov 5, 2025, 9:00 AM EST - 6 months ago

MannKind Earnings Call Transcript: Q3 2025


MannKind Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 9:45 AM EDT - 8 months ago

MannKind Transcript: Cantor Global Healthcare Conference 2025


MannKind to Present at Upcoming Investor Conferences

Aug 27, 2025, 4:05 PM EDT - 9 months ago

MannKind to Present at Upcoming Investor Conferences


MannKind Transcript: M&A Announcement

Aug 25, 2025, 8:30 AM EDT - 9 months ago

MannKind Transcript: M&A Announcement


MannKind Earnings Call Transcript: Q2 2025

Aug 6, 2025, 9:00 AM EDT - 9 months ago

MannKind Earnings Call Transcript: Q2 2025


MannKind Earnings Call Transcript: Q1 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

MannKind Earnings Call Transcript: Q1 2025


MannKind Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Earnings Call Transcript: Q4 2024


MannKind Expands Executive Leadership Team

Jan 6, 2025, 4:30 PM EST - 1 year ago

MannKind Expands Executive Leadership Team


MannKind Transcript: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

MannKind Transcript: Study Result


MannKind Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 1:15 PM EST - 1 year ago

MannKind Transcript: UBS Global Healthcare Conference 2024


MannKind Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

MannKind Earnings Call Transcript: Q3 2024


MannKind to Present at 2024 UBS Healthcare Conference

Nov 5, 2024, 4:15 PM EST - 1 year ago

MannKind to Present at 2024 UBS Healthcare Conference


More Adults With Type 1 Diabetes Achieved A1C Goal (

Sep 30, 2024, 6:00 AM EDT - 1 year ago

More Adults With Type 1 Diabetes Achieved A1C Goal (


MannKind Transcript: 2024 Wells Fargo Healthcare Conference

Sep 4, 2024, 11:00 AM EDT - 1 year ago

MannKind Transcript: 2024 Wells Fargo Healthcare Conference


MannKind to Present at Upcoming Conferences

Aug 27, 2024, 4:30 PM EDT - 1 year ago

MannKind to Present at Upcoming Conferences


Affizle
Affizle May. 9 at 3:18 AM
$MNKD Looks like Mike didn't buy those 100K shares after all. It was his wife. The stupid company mistakenly reported it was him but it wasn't. And it took the company two months to correct the mistake per the Form 4 released tonight. What a positively incompetent company Mannkind is. And it turns out the CEO's wife has bigger balls than her husband for buying shares out of pocket. 1. On March 10, 2026 Mr. Castagna filed a Form 4 that should not have been filed and which reported a transaction that should not, in fact, be attributable to him. The Form 4 mistakenly reported a direct acquisition of 100,000 shares of common stock of the Issuer on March 10, 2026 by Mr. Castagna (the "Shares"). The Shares, however, were acquired by Mr. Castagna's spouse under a segregated retirement account in which Mr. Castagna does not have a pecuniary interest. As a result, Mr. Castagna was not obligated to file a Form 4 pursuant to Section 16(a). Such Form 4 should be deemed revoked.
0 · Reply
jlonards
jlonards May. 9 at 1:02 AM
$MNKD I think we're good.
1 · Reply
Jw25nyc
Jw25nyc May. 8 at 10:39 PM
0 · Reply
grampslol
grampslol May. 8 at 8:42 PM
$MNKD remember the crappy scripts... New 292 refills 444... week ending 5/1/2026... approved in the USA in 2014...
0 · Reply
grampslol
grampslol May. 8 at 8:38 PM
$MNKD pennyland close...hump...
0 · Reply
zmanx
zmanx May. 8 at 8:32 PM
$MNKD nice c&h to get us back to $5-&6 range again
1 · Reply
Affizle
Affizle May. 8 at 8:15 PM
$MNKD who here also owns Lqda other than Clan, stevemano, and Nate? They stand to make a boat load of money on Monday. Lolz!
0 · Reply
ITrustno1
ITrustno1 May. 8 at 8:01 PM
$MNKD double PDUFA run up makes things interesting for all scenarios. Run up 1 incoming after the Q1 report sentiment dissipates next week. PDUFA 1 Approved Scenario What would the SELL THE NEWS crew do, knowing PDUFA 2 is set up just behind the 1st? PDUFA 1 CLR Scenario What would the SKY IS FALLING crew do, knowing PDUFA 2 is set up just behind the 1st? I don’t have an opinion on approval beyond the fact PDUfA 1 is an expansion for PEDS, so the drug is proven, the company has gotten through the FDA process for this specific product once already and should have a better understanding of what they needed to present to get this through. Volitility ahead for sure. Looking like Sub$3 isn’t going to hit… leveled off so far $3.5range +\- 15cents $4+ MIN looks to be the run up target over next two weeks IMO, just holding for a good re entry price myself.
0 · Reply
Kool_Aid_Mann
Kool_Aid_Mann May. 8 at 7:46 PM
$GME $AMC Come join $MNKD as they approach their May 29th pediatric PDUFA!! This is the one that they have been waiting for for 12 years. Lots of delays, but it is finally here and likely to be the milestone trigger for a big cash deal with big pharma! On top of that, they just got back the green light for Treprostinil DPI in IPF which had them previously trading over $6 until a spat with their partner $UTHR . Now, not only is everything copacetic again, but they have also just announced a new molecule colloboration with bigger potential than Trep, Ralinpag DPI! But wait, there's more, there is another PDUFA ahead for them for furoscix on July 26th, that will approve a new auto injector that will make this product best in class and reduce COGs by 70% to create massive profits. And lets not forget that nintedabib DPI just finished 1b and is prime for an upfront cash deal! Fireworks ahead, fight the Citadel!
1 · Reply
RockyRambo26
RockyRambo26 May. 8 at 7:30 PM
$MNKD Right now I think the shorts are crapping their pants trying to get out before the FDA approval this month!
5 · Reply
Harryx1
Harryx1 May. 8 at 7:22 PM
$MNKD Here’s my last 7 day BG average on Afrezza…Have a great weekend everyone.
5 · Reply
poiuytrewqasd
poiuytrewqasd May. 8 at 6:43 PM
$MNKD a contract with the VA would be ideal.
1 · Reply
stevemano
stevemano May. 8 at 6:01 PM
$MNKD I had a very old old friend who was a marine in Vietnam. Tell me yesterday that his diabetic doctor told him that she thought that AFREZZA she never heard of, but then said she thought that it would cause bacteria or mold in the lungs. I told him what I knew. But he was contrary to the idea. Many of the doctors in this country are either bought out or have their heads up their ass.
7 · Reply
bigskyliving
bigskyliving May. 8 at 5:31 PM
$MNKD Interesting news! The Trumpster is going to fire the head of the FDA. Well, how is that going to effect MNKD?
3 · Reply
jlonards
jlonards May. 8 at 5:25 PM
$MNKD August $5 calls were $.25 this AM.
0 · Reply
lutzbittner
lutzbittner May. 8 at 5:02 PM
$MNKD $MNKD Scripts Friday thanx for theTGIf info
0 · Reply
YolitheDolly
YolitheDolly May. 8 at 4:46 PM
$MNKD Earlier this week one of the resident pump monkeys posted $4 is the new floor. These pumpers are pathetic. They truly try to deceive and mislead like the shorts. They have no shame.
0 · Reply
bigskyliving
bigskyliving May. 8 at 4:29 PM
$MNKD Looks like another buying opportunity!
0 · Reply
DopeyCJ
DopeyCJ May. 8 at 4:23 PM
$MNKD this company is such garbage. Hard to believe inhaled insulin isn’t a blockbuster product. Bad marketing bad management
2 · Reply
grampslol
grampslol May. 8 at 3:56 PM
$MNKD he promised 5000 scripts weekly by 2017...and here he is derbying!
1 · Reply
Playthegame06
Playthegame06 May. 8 at 3:50 PM
$MNKD Also I didn’t hear anything about India nor MARGIN EXPANSION as a result of India.
1 · Reply
stevemano
stevemano May. 8 at 3:50 PM
$MNKD https://youtu.be/pCPSC_1Fdf8?si=kINPVpzT_xMnL5dK The FDA is not your buddy!
0 · Reply